WELKOM,   Inloggen   |   Registreren Trivano op Facebook Trivano op Twitter Volg Trivano via RSS  
Grafiek CrucellCrucell

CRXL | NL0000358562
Euronext Amsterdam
24,43 EUR   (0,10%)
Beleg goedkoper met Lynx
Kosten order 3.000 EUR: 6,00 EUR
Toevoegen aan Mijn Selectie   Aandeel toevoegen aan Mijn selectie
Samenvatting Profiel Dividend Kerncijfers Insiders Nieuws Persberichten Agenda Grafiek Koersen

Persberichten

Nieuws via RSS voor Crucell
15 maart 2011Crucell Intends to Delist Ordinary Shares on NYSE Euronext
09 maart 2011Johnson & Johnson Acquires 98.89% of Issued Crucell Shares as of the End of the Subsequent Offering Period and Crucell Intends to Delist Crucell Ordinary Shares and ADSs
22 februari 2011Johnson & Johnson Completes Tender Offer for Crucell and Declares Offer Unconditional
08 februari 2011Crucell Shareholders Adopt Offer Governance Resolutions and Johnson & Johnson Makes Announcement on U.S. Regulatory Matters
07 februari 2011Crucell Reports Fourth Quarter and Full Year 2010 Results
08 december 2010Johnson & Johnson Launches Recommended Public Offer to Acquire Crucell
01 december 2010Johnson & Johnson and Crucell Progress Update: Expect to Commence Public Offer Prior to 10 December 2010
09 november 2010Crucell Reports Third Quarter 2010 Results
29 oktober 2010Johnson & Johnson and Crucell Provide Progress Update on Preparations for Public Offer
29 oktober 2010Notice of Extraordinary General Meeting of Shareholders
28 oktober 2010Crucell Puts Temporary Hold on Shipments of Quinvaxem and Hepavax-Gene
14 oktober 2010Crucell to Convene Initial Informational Extraordinary General Meeting of Shareholders to Discuss Johnson & Johnson Offer
06 oktober 2010Johnson & Johnson and Crucell Reach Agreement on Intended Public Offer of EUR24.75 per Ordinary Share of Crucell
22 september 2010DSM and Crucell Announce Expansion of PERCIVIA PER.C6 Biopharmaceutical Joint Venture
22 september 2010Aeras and Crucell Announce Phase II Clinical Trial Start in Kenya
17 september 2010Johnson & Johnson and Crucell in advanced negotiations for an all cash public offer of EUR24.75 per ordinary share of Crucell
17 augustus 2010Crucell Reports Record Revenues in Second Quarter 2010
11 augustus 2010Crucell and Harvard (BIDMC) Join Forces with IAVI to Advance AdVac-based AIDS Vaccine
08 juli 2010Crucell Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines
24 juni 2010Crucell Announces Start of Universal RSV Vaccine Program

Oudere persberichten »